Definium Therapeutics, Inc. · NASDAQ:DFTX
Definium Therapeutics — Mind Medicine (MindMed) — Investor Presentation (April 2022)
36 slides from Definium Therapeutics's investor presentation, Apr 26, 2022
Slide 1: MindMed Corporate Overview April 2022
MindMed Corporate Over April 2022
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc. (“MindMed” or the “Company”) solely for informational purposes. None of MindMed, its affiliates or any of their respective employees, directors, officers, contractors, advisors, members, successors, r
Slide 3: Business Highlights
Business Highlights Our mission is to deliuer on the therapeutic potential of psychedelics and other nouel targets to treat brain health disorders • Leader in developing psychedelic product candidates to treat brain health disorders • Diversified pipeline of clinical programs targeting significant u
Slide 4: There is an Urgent Need for Better Treatments
There is an Urgent Need for Better Treatments Substantial opportunities exist to advance novel treatments for a wide range of brain health disorders >- â–¡J 1-year prevalence of anxiety 7 | /O disorders in the US2 • • • • • ’ W W W W 15 0 M “”” Q people in the US overdosed W W W W Ww Q on opioids in
Slide 5: Advancing Multiple Generations of Drug Candidates
Advancing Multiple Generations of Drug Candidates Our strategy is to deliver on well-characterized psychedelic candidates and next generation candidates with enhanced drug profiles 1 o • Expanded clinical indications • Clinical evidence of efficacy /H3 * N N CLASSIC HC^ ‘ Psychedelics with distinct
Slide 6: Research & Development Pipeline
Research & Development Pipeline Our pipeline diversification offers potential opportunities across therapeutic areas and mechanisms of action PSYCHIATRY ADHD MM-402 (R(-)-MDMA) Autism Spectrum Disorder SUBSTANCE USE DISORDERS MM-110 (zolunicant HCI) Opioid Withdrawal PAIN DISCOVERY & EARLY DEVELOPME
Slide 7: Upcoming Portfolio Milestones
Upcoming Portfolio Milestones MindMed’s clinical research portfolio creates multiple near-term and intermediate catalysts PSYCHIATRY MM-120 (LSD D-tartrate) Generalized Anxiety Disorder S ADHD MM-402 (R(-)-MDMA) Autism Spectrum Disorder SUBSTANCE USE DISORDERS /â– HWWWWIk MM-110 (zolunicant HCI) Opi
Slide 8: Advancing the Field with Strong IP & Strategic Competitive Moats
Advancing the Field with Strong IP & Strategic Competitive Moats Our approach is to protecting innovation and market potential through intellectual property-oriented R&D strategies Strategic Life Cycle Management & Late-Stage IP for Innovation Development Can Significantly Extend Market Protection &
Slide 9: MM-120 Milestones
LSD-Anxiety Topline Readout Q2 2022 | Phase 2 (IIT) GAD First Patient Dosing >1 I 2022 phase Chronic Pain Study Initiation Q4 2022 | Phase 2 ESOE MindMed Corporate Overview | April 2022 9
Slide 10: MM-120 | Lead Candidate with Evidence Across Multiple Therapeutic Areas
MM-120 | Lead Candidate with Evidence Across Multiple Therapeutic Areas Extensive evidence of clinical benefit and mechanistic rationale in psychiatry, pain and substance use disorders 1 Rapid & sustained 3x Effect Size benefit after acute dosing1 compared to available affective disorder therapies2
Slide 11: MM-120 | Emerging Treatment Paradigm for Brain Health Disorders
MM-120 | Emerging Treatment Paradigm for Brain Health Disorders Novel mechanisms of action with transdiagnostic applicability Global Brain Connectivity / Placebo (Low Entropy) Psychedelic drug (High Entropy) I Increased single neuron excitability Layer V v-fj & Psychedelic pyramidal A drug delivered
Slide 12: MM-120 | Legacy of LSD Clinical Research in Psychiatric Disorders
MM-120 | Legacy of LSD Clinical Research in Psychiatric Disorders Building on decades of clinical research on LSD in anxiety and depression 21 STUDIES Anxiety, depression & 512 patients Up to 95% reduction in PRIOR T019741 ‘neuroses’ symptoms GASSER 20142 Anxiety in 12 patients Effect size of 1.1 wi
Slide 13: MM-120 | Phase 2b Generalized Anxiety Disorder (GAD)
MM-120 | Phase 2b Generalized Anxiety Disorder (GAD) Study design seeks to demonstrate dose-responsive effects and identify optimal dose for pivotal clinical trials PSYCHIATRY MM-120 (LSD D-tartrate) Indication: GAD 200 participants total (n=40/arm) HMHM M H ^B Phase Dose Week | J |^^B^^B ^^1 ‘ ^B^B
Slide 14: MM-120 | Phase 2a ADHD
MM-120 | Phase 2a Attention Deficit Disorder (ADHD) Proof of concept study design seeks to explore potential clinical response in ADHD PSYCHIATRY MM-120 (LSD D-tartrate) Indication: ADHD 52 participants total (n=26/arm) A Phase 2a Proof of Concept Study Week LOW ^OSES for the Treatment of ADHD in Ad
Slide 15: MM-120 | Novel Applications in Chronic Pain
MM-120 | Novel Applications in Chronic Pain Preclinical and early clinical evidence provide support for unique mechanism of action and potential clinical activity KAST 1967 Terminal cancer pain 128 patients 100 ug reduced cumulative pain scores for at least 12 hours post-treatment 2 FANCIULLACCI 197
Slide 16: MM-110 Milestones
Phase 1 Topline Data Readout Q2 2022 | Phase 1 Opioid W/D Study Initiation Q2 2022 | Phase 2a Opioid W/D ESOE Readout Q4 2022 | Phase 2a (Part A) MindMed Corporate Overview | April 2022 16
Slide 17: MM-110 | Novel Mechanism to Address a Critical Gap in OUD Treatment
MM-110 | Novel Mechanism to Address a Critical Gap in OUD Treatment Mechanism of action and target product profile complement standard-of-care and address a critical gap in available treatment landscape Opioid Initiation Opioid Use Disorder MM-110-facilitated Medication Assisted Therapies (MAT) Supe
Slide 18: MM-110 | Strong Preclinical Efficacy on Key Translational Outcomes
MM-110 | Strong Preclinical Efficacy on Key Translational Outcomes A single dose of MM-110 mitigates withdrawal symptoms and opioid self-administration in preclinical models12 Reduction in Translational Markers of Opioid Withdrawal Reduction in Translational Markers of OUD 125 30 20 I Control 10 20
Slide 19: MM-110 | Phase 2a Supervised Withdrawal in Opioid Use Disorder
MindMed Corporate Overview | April 2022 1J MM-110 | Phase 2a Supervised Withdrawal in Opioid Use Disorder Gated two-part study design provides opportunity for early signs of efficacy (ESOE) and informs randomized proof of concept design SUBSTANCE USE DISORDERS MM-110 (zolunicant HCI; 18-MC) Indicati
Slide 20: Key Milestones
Key Milestones PK/PD Study Initiation MM-402 Phase 1 Study Initiation 2023 | Phase 1 R(-)-MDMA ) MindMed
Slide 21: No Approved Drugs for Core Symptoms of Autism Spectrum Disorder (ASD)
No Approved Drugs for Core Symptoms of Autism Spectrum Disorder (ASD) Growing prevalence and impact of ASD yields an urgent need for novel therapies that target core symptoms and align with patient preferences MM-402 Activity Aligns with Reported Needs and Desired Benefits for Individuals with ASD I
Slide 22: MM-402 | Clinical Data Support Opportunity in ASD
Leigh & Du 2015; J. Autism Dev. Disord. 45(12). 2. Kogan, Pediatrics 2018; 142(6). 3. FDA Patient Focused Drug Development workshop on Autism Spectrum Disorder (2017) MindMed Corporate Overview | April 2022 21 MM-402 | Clinical Data Support Opportunity in ASD Pilot clinical trial results of MDMA dem
Slide 23: MM-402 | Preclinical Data Indicate Potential Enhanced Benefit/Risk Profile
MM-402 | Preclinical Data Indicate Potential Enhanced Benefit/Risk Profile Preclinical data suggest the R-enantiomer of MDMA has enhanced prosocial effects with an improved safety profile K| f kit- Ip fcl I j I R(-)-MDMA Maintains Prosocial Effects with • Strong prosocial effects 2 200% • Less stimu
Slide 24: Collaborations & Early R&D
Collaborations & Early R&D
Slide 25: External Collaborations Accelerate Discovery & Development
External Collaborations Accelerate Discovery & Development Leveraging key partnerships and collaborations to accelerate drug discovery and de-risk clinical development DISCOVERY & BRAIN TARGETED LIPOSOMES RAPID DATA GENERATION & LEAD OPTIMIZATION (BTLS) CLINICAL CONCEPT TESTING MindShift wnextage ^r
Slide 26: Exclusive Collaboration with Leading Researchers
Exclusive Collaboration with Leading Researchers MindMed’s exclusive collaboration with the Liechti Lab at UHB enables efficient evidence generation to support R&D strategy for (7m7) • Rapid transition to LSDforMDD clinical evidence generation LSD for Cluster Headache De-risk clinical indications MD
Slide 27: Digital Medicine
Digital Medicine MindMed
Slide 28: Digital Unlocks Potential Opportunities Throughout the Product Lifecycle
Digital Unlocks Potential Opportunities Throughout the Product Lifecycle Generating data, insights, models, and tools from early development through market management Preclinical Research IND & Phases 1—3 Drug Launch Enhancement and Lifecycle Management • Deep Digital Diagnoses • Decision Support •
Slide 29: Digital Platform Will Add Value Through the Patient Journey
Digital Platform Will Add Value Through the Patient Journey Developing a scalable delivery platform to enable adoption leveraging the existing treatment ecosystem • Patient education, engagement, preparation • In-session monitoring • Real world monitoring of trends • Deep digital diagnosis • Clinici
Slide 30: Digital Enables Alignment of Incentives for Broad Market Access
Digital Enables Alignment of Incentives for Broad Market Access Complementary digital medicine products and studies for improved brain health outcomes J Measure, Diagnose & Engage Connect A Performance, 2 Outcome, Community Support Trends i \ / Quality care & documentation I 1 • • , cl.. ld.. rt aUl
Slide 31: Digital Pipeline Progression Aligns with Drug Development
Digital Pipeline Progression Aligns with Drug Development Executing across product categories with strong technical development and clinical research TECHNOLOGY CANDIDATE In Development — Concept candidate DISCOVERY & REAL-WORLD DATA In Development In Development — Concept development — Concept deve
Slide 32: Corporate Information
Corporate Information
Slide 33: First Publicly Listed Company Developing Psychedelic Product Candidates
NASDAQ: MNMD // NEO: MMED First Publicly Listed Company Developing Psychedelic Product Candidates EXECUTIVE TEAM/DIRECTORS/INSIDERS 44,796,490 9.2% O A ~ ! I I J million NON-INSIDER SHARES 377,108,827 76.8% Raised since inception including warrants EQUITY INCENTIVE PLAN (ISSUED) 46,269,703 9.4% OUTS
Slide 34: Leadership: Leading Expertise in Innovative Drug & Digital Development
MindMed Corporate Overview | April 2022 33 Leadership: Leading Expertise in Innovative Drug & Digital Development Robert Barrow If Miri Halperin Wernli, PhD Cynthia Hu, JD Rob is an accomplished pharmaceutical executive and clinical pharmacologist with Miri co-founded Creso Pharma, a cannabis compan
Slide 35: Scientific Advisory Board
Robert Malenka, MD, PhD Maria A Oquendo, MD, PhD Maurizio Fava, MD Chairman of the Scientific Advisory Board, Nancy Friend Pritzker Professor in Ruth Meltzer Professor and Chairman of Psychiatry at University of Pennsylvania, Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH), directo
Slide 36: MindMed
MindMed MindMed Corporate Overview | April 2022 36
Mind Medicine (MindMed) — Investor Presentation (April 2022) on 6ix